News

July 19, 2019

Prophylactic anti-TNF Therapy Improves Safety of Immunotherapies, Mouse Study Says

News

Prophylactic anti-TNF therapy improves the safety and, to some degree, the efficacy of checkpoint blockade combination immunotherapies, a mouse study says. The findings of the study, “Prophylactic TNF blockade ... Read more

July 17, 2019

Transgene Completes Enrollment for Phase 2 Trial of Triple Combo NSCLC Therapy

News

Transgene has completed patient enrollment for its Phase 2 trial evaluating the cancer vaccine TG4010 in combination with Opdivo (nivolumab) and chemotherapy as a first-line treatment for advanced non-squamous ... Read more

July 16, 2019

FDA Will Review Application Seeking Expansion of Keytruda’s Dosing Schedule

News

The U.S. Food and Drug Administration (FDA) has accepted for review six supplemental biologics license applications (sBLAs) seeking to expand the dosing schedule of Keytruda (pembrolizumab) so the medication ... Read more

July 12, 2019July 12, 2019

Libtayo Approved in Europe to Treat Metastatic or Advanced Cutaneous Squamous Cell Carcinoma

News

Libtayo (cemiplimab) has been conditionally approved to be sold in the European Union for the treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC), one ... Read more

July 10, 2019

Trial Will Test Thermal Ablation, Followed By IP-001 Immunotherapy, Against Solid Tumors

News

Immunophotonics and Clinical Laserthermia Systems (CLS) are teaming up in a Phase 1/2 trial to explore the safety and effectiveness of a thermal ablation approach — destruction of tissue ... Read more

July 9, 2019July 9, 2019

Cancer Vaccine VBI-1901 Well-Tolerated in Recurrent Glioblastoma Patients, Early Phase 1/2a Data Show

News

Treatment of recurrent glioblastoma with the investigational cancer vaccine VBI-1901 was well-tolerated and associated with stable disease in a subset of patients, according to findings of a Phase 1/2a ... Read more

July 3, 2019

Imfinzi Combo Therapy Extends Survival of Advanced SCLC Patients, Phase 3 Trial Shows

News

Adding Imfinzi (durvalumab) to standard first-line chemotherapy led to a clinically meaningful extension in the overall survival of patients with advanced small cell lung cancer (SCLC), according to results ... Read more

July 2, 2019

DPX-Survivac-Keytruda Trio Shows Promise in DLBCL Patients

News

IMV‘s lead candidate, DPX-Survivac, in combination with Keytruda (pembrolizumab) and low-dose intermittent cyclophosphamide, eliminated radiologic traces of cancer cells in one-third of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) ... Read more

June 28, 2019June 28, 2019

Complete Remission Induced in B-cell ALL Patients After Single Dose of FasT CAR-19 Therapy, Preliminary Data Show

News

A single infusion of an experimental cell therapy called FasT CAR-19 was well-tolerated and induced a complete remission in all B-cell acute lymphoblastic leukemia (B-ALL) patients included in a ... Read more

June 26, 2019

Tislelizumab Produces Promising Anti-Cancer Activity in Advanced Nasopharyngeal Cancer Patients, Preliminary Data Show

News

BeiGene’s investigational anti-PD-1 inhibitor tislelizumab is well-tolerated and showed early signs of efficacy in patients with advanced nasopharyngeal cancer, with more than 40% of patients achieving a response to ... Read more

Pin It on Pinterest